Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs have been updated today, Feb. 1, 2021:
Effective March 1, 2021:
- IL-4 Inhibitor
- Oral Anticoagulant
- SA Oncology
- Soliris and Ultomiris
- Amifampridine
- Ampyra
- Arikayce
- ATTR Amyloidosis Onpattro
- ATTR Amyloidosis
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.